Literature DB >> 18178454

The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability.

Nikolaos P E Kadoglou1, Thomas Gerasimidis, Spyretta Golemati, Alkistis Kapelouzou, Panayiotis E Karayannacos, Christos D Liapis.   

Abstract

OBJECTIVE: Osteopontin (OPN) and osteoprotegerin (OPG) are well-known vascular calcification inhibitors, which have been recently demonstrated to correlate with inflammation and cardiovascular events incidence. The aim of this cross-sectional study is to survey whether OPN and OPG are involved in carotid plaque vulnerability. For this reason, we assessed serum OPN and OPG levels in patients with carotid stenosis, and we explored their relationship with carotid plaque echogenicity and subsequent cerebrovascular ischemic events.
METHODS: A total of 164 Whites were selected from a large cohort of 297 subjects to participate. In particular, 114 patients (61 men, 53 women), aged 55 to 80, had recently-diagnosed ICA stenosis higher than 50%. A group of 50 age-, sex-, and body mass index (BMI)-matched healthy individuals served as healthy controls. Patients with renal failure, hypothyroidism, osteoporosis, and lipid-lowering therapy were excluded. Images of both carotids were obtained from all participants using a high-resolution color duplex ultrasound and the gray-scale median (GSM) score was calculated. Brain computed tomography (CT), and magnetic resonance imaging (MRI) scans when CT was questionable, were performed on all patients with carotid stenosis. Clinical parameters, lipid and glycemic indexes, hsCRP, fibrinogen, white blood cells (WBC) count, OPN, and OPG were measured. Independent t test, one-way ANOVA, Pearson correlation, and multiple regression analysis were used for statistical analysis.
RESULTS: Among patients with carotid stenosis, 60 had history of ipsilateral stroke or TIA and positive CT or MRI findings (group A), while 54 had no neurological symptoms and negative CT and MRI scan (group B). Overall, patients with carotid stenosis showed worse lipid profile and increased waist circumference, blood pressure, hsCRP, fibrinogen, WBC count, OPN, and OPG levels compared with healthy subjects (group C) (P <.05). Statistical analysis revealed that group A had significantly lower levels of GSM than group B (57.41 +/- 38.19 vs 76.32 +/- 36.72; P = .008) and higher levels of hsCRP, OPN, and OPG than groups B and C (P < .05). Concerning the latter, biochemical markers group B showed only elevated OPG levels compared with group C (P = .038). Notably, GSM was considerably associated with serum OPN and OPG and waist circumference in patients with carotid atherosclerosis in univariate (r = -0.333; P = .032, r = -0.575; P < .001, r = -0.590; P =.006, respectively) and multiple regression analysis (R(2) = 0.445; P =.006).
CONCLUSIONS: The present study demonstrated elevated serum OPN and OPG levels in patients with carotid stenosis and documented an independent association between these biochemical markers, GSM and carotid-induced symptomatology. Therefore bone-matrix proteins combined with GSM could be potential markers for vulnerable carotid plaques.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178454     DOI: 10.1016/j.jvs.2007.09.058

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  25 in total

1.  Urinary Osteopontin Predicts Incident Chronic Kidney Disease, while Plasma Osteopontin Predicts Cardiovascular Death in Elderly Men.

Authors:  Tobias Feldreich; Axel C Carlsson; Johanna Helmersson-Karlqvist; Ulf Risérus; Anders Larsson; Lars Lind; Johan Ärnlöv
Journal:  Cardiorenal Med       Date:  2017-05-25       Impact factor: 2.041

Review 2.  Osteoporosis--a risk factor for cardiovascular disease?

Authors:  Christos E Lampropoulos; Ioanna Papaioannou; David P D'Cruz
Journal:  Nat Rev Rheumatol       Date:  2012-08-14       Impact factor: 20.543

3.  Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case-control study (The OSMOSIS Study).

Authors:  Julie Contenti; Matthieu Durand; Sandor Vido; Serge Declemy; Juliette Raffort; Joseph Carboni; Sophie Bonnet; Christophe Koelsch; Réda Hassen-Khodja; Philippe Gual; Nathalie M Mazure; Nirvana Sadaghianloo
Journal:  J Nephrol       Date:  2021-09-01       Impact factor: 3.902

4.  Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.

Authors:  Pinar Demir; Fusun Erdenen; Hale Aral; Turker Emre; Sennur Kose; Esma Altunoglu; Anil Dolgun; Berrin Bercik Inal; Aydin Turkmen
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

Review 5.  Osteoprotegerin, vascular calcification and atherosclerosis.

Authors:  Ann Van Campenhout; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2008-10-09       Impact factor: 5.162

6.  Osteopontin and osteoprotegerin in atherosclerotic plaque - are they significant markers of plaque vulnerability?

Authors:  Cristina Strobescu-Ciobanu; Simona Eliza Giuşcă; Irina Draga Căruntu; Cornelia Amălinei; Andreea Rusu; Elena Cojocaru; Radu Florin Popa; Cristian Dumitru Lupaşcu
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

7.  Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction.

Authors:  Lajos Fehérvári; Attila Frigy; Lóránd Kocsis; István Adorján Szabó; Timea Magdolna Szabo; Melinda Urkon; Zita Jakó; Előd Ernő Nagy
Journal:  Diagnostics (Basel)       Date:  2021-04-24

8.  Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.

Authors:  Constantinos Giaginis; Aikaterini Papadopouli; Athina Zira; Athanasios Katsargyris; Christos Klonaris; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2012-10

Review 9.  The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.

Authors:  Daniela-Eugenia Malliga; Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2011-09-02

10.  Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma.

Authors:  Catherine L Higgins; Salim Isbilir; Pamela Basto; Iou Yih Chen; Muthiah Vaduganathan; Periyanan Vaduganathan; Michael J Reardon; Gerald Lawrie; Leif Peterson; Joel D Morrisett
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.